Research Topics
Genomes and GenesSpecies | F PaciniSummaryAffiliation: University of Siena Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus reportFurio Pacini
University of Siena, Siena, Italy
Eur J Endocrinol 153:651-9. 2005..To determine, based on published literature and expert clinical experience, current indications for the post-surgical administration of a large radioiodine activity in patients with differentiated thyroid cancer...
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levelsGiuseppe Martini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Internal Medicine, University of Siena, Siena, Italy
Thyroid 18:455-60. 2008....- Management of differentiated thyroid cancer of the follicular epitheliumFurio Pacini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Italy
Ann Med 44:651-5. 2012..In view of this change in the presentation of the disease, the objective of thyroid cancer management should be aimed at achieving complete cure using the less aggressive diagnostic and therapeutic procedures... - Expression of the ring ligase PRAJA2 in thyroid cancerSilvia Cantara
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology, and Metabolism and Biochemistry, Policlinico Santa Maria alle Scotte, Viale Bracci 1, University of Siena, 53100 Siena, Italy
J Clin Endocrinol Metab 97:4253-9. 2012..Differentiated thyroid cancer expresses a functional TSH receptor, and its growth and progression are positively regulated by TSH and cAMP signaling... - New insight in the follow-up strategies of differentiated thyroid cancerF Pacini
Section of Endocrinology and Metabolism, University of Siena, Siena, Italy
J Endocrinol Invest 35:36-9. 2012.... - Thyroid microcarcinomaFurio Pacini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Via Bracci, 53100 Siena, Italy
Best Pract Res Clin Endocrinol Metab 26:421-9. 2012.... - Thyroid microcarcinomaFurio Pacini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Via Bracci, 53100 Siena, Italy
Best Pract Res Clin Endocrinol Metab 26:381-9. 2012.... - Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancerSilvia Cantara
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism, and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 97:E1327-31. 2012..Studies carried out in our unit have demonstrated that familial papillary thyroid cancer (fPTC) patients display an imbalance, at the germinal level, in telomere-telomerase complex... - Approach to and treatment of differentiated thyroid carcinomaFurio Pacini
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, VialeBracci 1, 53100 Siena, Italy
Med Clin North Am 96:369-83. 2012..This review addresses the multiple steps of current management, based on previous assumptions... - Management of thyroid nodules: a clinicopathological, evidence-based approachFurio Pacini
Section of Endocrinology and Metabolism, University of Siena, Siena, Italy
Eur J Nucl Med Mol Imaging 31:1443-9. 2004..This review aims to offer a practical approach to the management of nodular thyroid disorders, considering the way in which the pathophysiology of the disease provides clues to the correct clinical diagnosis and therapy... - Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancerFurio Pacini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Italy
Best Pract Res Clin Endocrinol Metab 22:1009-21. 2008..This review will focus on the clinical application of rhTSH in the management of DTC, highlighting current indications and future perspectives... - European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumFurio Pacini
Section of Endocrinology and Metabolism, University of Siena, Via Bracci, 53100 Siena, Italy
Eur J Endocrinol 154:787-803. 2006 - Targeted therapy in radioiodine refractory thyroid cancerF Pacini
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Siena, Italy
Q J Nucl Med Mol Imaging 53:520-5. 2009..This review will summarize the most relevant achievements in the field and will discuss the limit and perspective of the new compounds... - Medullary thyroid carcinomaF Pacini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Siena, Italy
Clin Oncol (R Coll Radiol) 22:475-85. 2010..Carriers of the RET gene are candidates for prophylactic thyroidectomy at different ages depending on the risk associated with the specific RET mutations... 
Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancerSilvia Cantara
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Siena, Italy
Thyroid Res 3:4. 2010..We concluded that the A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) is not correlated with the familial form of PTC, even when the tumor was in the context of multinodular goiter...- Telomerase and the endocrine systemFurio Pacini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Siena 53100, Italy
Nat Rev Endocrinol 7:420-30. 2011..A number of studies have demonstrated unequivocally that reactivation of telomerase in the presence of short telomeres is one of the most common features of human cancers, including those of the endocrine system... - Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancerMarco Capezzone
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 96:E1852-6. 2011..Recently, we have reported that patients with the familial form of papillary thyroid cancer (FPTC) have short telomeres in blood leucocytes... - Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patientsHernan P Tala Jury
University of Siena, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 95:230-7. 2010..Low-iodine diet is prescribed before (131)I administration in patients with differentiated thyroid cancer, although no study has properly quantified its clinical benefit... - The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinomaM G Castagna
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, 53100 Siena, Italy
J Endocrinol Invest 34:e219-23. 2011..Our study indicates that the combination of neck ultrasound and basal ultrasensitive Tg allows to identify all patients free of disease and can decrease the need for rhTSH stimulation in nearly 80% of the patients... - Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levelsM G Castagna
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 93:76-81. 2008..One year after initial treatment, low-risk differentiated thyroid cancer (DTC) patients undergo recombinant human (rh)TSH-stimulated serum thyroglobulin (Tg) (rhTSH-Tg) and neck ultrasound (US)... - Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-upF Pacini
Department of Internal Medicine, University of Siena, Siena, Italy
Ann Oncol 19:ii99-101. 2008 - Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entityM Capezzone
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy
Endocr Relat Cancer 15:1075-81. 2008..04) when compared with the first generation. In conclusion, FNMTC displays the features of clinical 'anticipation' with the second generation acquiring the disease at an earlier age and having more advanced disease at presentation... - A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancerTania Pilli
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Nuclear Medicine, University of Siena, 53100 Sienna, Italy
J Clin Endocrinol Metab 92:3542-6. 2007..We investigated whether 1850 MBq (131)I had a similar successful rate to 3700 MBq in patients prepared with rhTSH... - Serum ghrelin levels in growth hormone-sufficient and growth hormone-deficient patients during growth hormone-releasing hormone plus arginine testB Tarantini
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Via Bracci, 53100 Siena, Italy
J Endocrinol Invest 32:335-7. 2009..We evaluated the circulating ghrelin levels in GH-deficient (GHD) and in GH-sufficient (GHS) patients during GHRH plus arginine test... - Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancerElisa Guarino
Department of Internal Medicine, Endocrinology and Metabolism, Section of Endocrinology and Metabolism, University of Siena, Italy
Thyroid 15:1041-5. 2005..In conclusion, this study failed to show any prognostic value of presurgical serum thyroglobulin determination that consequently should not be measured... - Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidismB Tarantini
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, 53100 Siena, Italy
J Endocrinol Invest 29:594-8. 2006..No influence was found between outcome and clinical parameters at the moment of 131-I therapy. In conclusion, our results indicate that RAI therapy is highly effective and safe for the control of hyperthyroidism... - L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodiesSerenella Checchi
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, 53100 Siena, Italy
J Clin Endocrinol Metab 93:465-9. 2008..Hypothyroid patients on l-T(4) therapy may require replacement doses exceeding the theoretical needs to normalize serum TSH due to low patient compliance, drugs interference, and malabsorption... - Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytologySilvia Cantara
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology, and Metabolism and Biochemistry, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 95:1365-9. 2010..0%). Conclusions: Our findings demonstrate that molecular analysis of cytological specimens is feasible and that its results in combination with cytology improves the diagnostic performance of traditional cytology... - Ultrasound examination using contrast agent and elastosonography in the evaluation of single thyroid nodules: Preliminary resultsF S Ferrari
Diagnostica per Immagini, Performance srl, Siena, Italy
J Ultrasound 11:47-54. 2008..To evaluate the usefulness of ultrasound (US) using contrast agent and elastosonography in the characterization of thyroid nodules... - Multinodular goiter of unusual shape and locationLucia Brilli
Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, Section of Endocrinology, University of Siena, Siena, Italy
Thyroid 17:693-4. 2007 - Role of percutaneous ethanol injection in management of nodular lesions of the thyroid glandFurio Pacini
University of Siena, Siena, Italy
J Nucl Med 44:211-2. 2003 - Guidelines for diagnosis and therapy of MEN type 1 and type 2M L Brandi
Department of Internal Medicine, University of Florence, 50139 Florence, Italy
J Clin Endocrinol Metab 86:5658-71. 2001.... - Targeted therapy in refractory thyroid cancer: current achievements and limitationsLucia Brilli
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Viale Bracci 1, 53100 Siena, Italy
Future Oncol 7:657-68. 2011..The aim of this article is to describe the benefits and limitations of innovative drugs that are currently under investigation in patients with refractory thyroid cancer... - Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patientsMarco Capezzone
Department of Internal Medicine, University of Siena, Policlinico Santa Maria alle Scotte, 53100 Siena, Italy
J Clin Endocrinol Metab 93:3950-7. 2008..Differentiated papillary thyroid cancer is mostly sporadic, but the recurrence of the familial form has been reported. Short or dysfunctional telomeres have been associated with familial benign diseases and familial breast cancer... - Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodiesSerenella Checchi
Section of Endocrinology and Metabolism, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 92:4346-51. 2007..We studied the diagnostic use of the measurement of serum ghrelin compared with other markers of gastric damage in predicting the presence of ABG in patients with autoimmune gastritis... - Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspectiveMartin Schlumberger
Institut Gustave Roussy, Villejuif, France
Eur J Endocrinol 150:105-12. 2004..We sought to develop an improved protocol for the follow-up of low-risk patients with DTC based on the findings of recent studies... - Expanding indications for recombinant human TSH in thyroid cancerBryan R Haugen
Thyroid 18:687-94. 2008 - The effect of short-term treatment with recombinant human thyroid-stimulating hormones on leydig cell function in menJoaquin Lado-Abeal
Department of Medicine, The University of Chicago Medical Center, Chicago, Illinois 60637, USA
Thyroid 13:649-52. 2003..In conclusion, short-term elevations in serum TSH levels in the range reported in hypothyroid boys with precocious puberty did not increase serum testosterone levels in adult men... - A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawalPamela R Schroeder
Johns Hopkins Medical Institutions, Division of Endocrinology and Metabolism, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
J Clin Endocrinol Metab 91:878-84. 2006..CONCLUSIONS: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use... - Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigensLuca Chiovato
, Pisa, Italy
Ann Intern Med 139:346-51. 2003.... - Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancerFerruccio Santini
Department of Endocrinology, University of Pisa, 56124 Pisa, Italy
J Clin Endocrinol Metab 87:4160-5. 2002..In conclusion, the response rate of poorly differentiated thyroid cancer to chemotherapy observed in this study was favorable and promising. TSH stimulation may have contributed to these results... - Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawalFurio Pacini
Department of Endocrinology and Metabolism, University of Pisa, 56124 Pisa, Italy
J Clin Endocrinol Metab 87:4063-8. 2002.... - rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive reviewMarkus Luster
Department of Nuclear Medicine, University of Wurzburg, Josef Schneider Str 2, 97080 Wurzburg, Germany
Endocr Relat Cancer 12:49-64. 2005.... - Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinomaMaria Grazia Castagna
Department of Endocrinology and Metabolism, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy
J Clin Endocrinol Metab 90:4047-50. 2005..CONCLUSIONS: With this study we demonstrated that LBM is the only parameter independently associated with serum peak TSH after rhTSH administration. However, the serum peak TSH does not influence the rate of (131)I remnant ablation... - Follow-up of differentiated thyroid cancerFurio Pacini
Department of Endocrinology, University of Pisa, Ospedale Cisanello, Via Paradisa 2, 56124 Pisa, Italy
Eur J Nucl Med Mol Imaging 29:S492-6. 2002..Using this strategy, most patients will achieve definitive cure and will have a normal quality of life... - How the availability of recombinant human TSH has changed the management of patients who have thyroid cancerMartin Schlumberger
University Paris Sud, Paris, France
Nat Clin Pract Endocrinol Metab 3:641-50. 2007.... - Thyroid cancer in children and adolescentsFurio Pacini
J Endocrinol Invest 25:572-3. 2002 - Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patientsRossella Elisei
Department of Endocrinology and Metabolism, University of Pisa, 56124 Pisa, Italy
J Clin Endocrinol Metab 89:33-9. 2004..On the contrary, serum Tg measurement is a very sensitive and specific thyroid tumor marker, and we recommend that the follow-up of patients affected by DTC must be performed using serum Tg rather than blood Tg mRNA measurement... - Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalHeribert Hänscheid
Klinik und Poliklinik fur Nuklearmedizin, Universitat Wurzburg, D 97080 Wurzburg, Germany
J Nucl Med 47:648-54. 2006..7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented... - Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practiceMartin Schlumberger
service de Medicine Nucleaire, Institut Gustave Roussy, 94805 Villejuif, France
Eur J Endocrinol 151:539-48. 2004..We also offer expanded and additional comments on various issues in the management of DTC... - Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimensRiccardo Giannini
Department of Oncology, University of Pisa, Pisa, Italy
Thyroid 13:765-70. 2003.... - Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypesAgnese Vivaldi
Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa School of Medicine, 56100 Pisa, Italy
J Clin Endocrinol Metab 88:892-9. 2003..The presence of the SV40 footprint in PBMC implies that blood cells are vectors of the virus in other tissues of the host... - Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completenessPaolo Miccoli
Department of Surgery, University of Pisa, S. Chiara Hospital, Via Roma 67, 56100 Pisa, Italy
Surgery 132:1070-3; discussion 1073-4. 2002..No conclusions can be drawn in terms of influence of MIVAT on the outcome of the patients with small papillary thyroid carcinoma... - Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangementFulvio Basolo
Dipartimento di Oncologia, Universita degli Studi di Pisa, Pisa, Italy
Int J Cancer 97:608-14. 2002..Moreover, FB-2 cells produced high levels of interleukin (IL)-6 and IL-8... - Why do we need guidelines for differentiated thyroid cancer?Furio Pacini
Thyroid 16:103-4. 2006 - Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disordersRossella Elisei
Department of Endocrinology and Metabolism, University of Pisa, 56124 Pisa, Italy
J Clin Endocrinol Metab 89:163-8. 2004..On this basis, routine measurement of basal serum CT levels should be considered an integral part of the diagnostic evaluation of thyroid nodules... - Biology and clinical application of the NIS geneRossella Elisei
Department of Endocrinology and Metabolism, University of Pisa, Italy
Tumori 89:523-8. 2003..This has demonstrated the feasibility of the in vitro technique but also raised the problem of the absence of the iodide organification machinery in non-thyroidal cells, which, at the moment, represents the major limit of this strategy... - Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acidRossella Elisei
Department of Endocrinology and Metabolism, Via Paradisa 2, University of Pisa, 56124 Pisa, Italy
J Clin Endocrinol Metab 91:2389-95. 2006..One of the major limits of gene therapy with sodium iodide symporter (NIS), which enables cells to be subjected to radioiodine therapy, is that NIS-transfected cells rapidly release the intracellular iodine... - RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentrationRossella Elisei
Department of Endocrinology and Metabolism, University of Pisa, 56124 Pisa, Italy
Thyroid 15:1355-61. 2005.... - RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one centerRossella Elisei
Department of Endocrinology, University of Pisa, Via Paradisa 2, 56100 Pisa, Italy
J Clin Endocrinol Metab 92:4725-9. 2007.... - Clinical features and therapeutic implication of papillary thyroid microcarcinomaKalliopi Pazaitou-Panayiotou
Department of Endocrinology Endocrine Oncology, Theaghenion Cancer Hospital, 2 Al Simeonidi Street, Thessaloniki, Greece
Thyroid 17:1085-92. 2007..Distant metastases are extremely rare, but have been reported. Although deaths related to PTM are almost unknown, PTM raises therapeutic implications. This review addresses the issue of definition, treatment, and follow-up of PTM... - Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up studyRossella Elisei
Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy
J Clin Endocrinol Metab 93:682-7. 2008..The aim of this study was to verify the prognostic value of somatic RET mutations in a large series of MTCs with a long follow up... - Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteriaFurio Pacini
Thyroid 18:279-80. 2008 - Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behaviorRosa Paula Biscolla
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
Thyroid 14:946-52. 2004..Moreover, although we cannot completely exclude a shared pathogenic event as the cause of both MTC and PTC, the molecular analysis of RET gene alterations did not show any common mutation... - Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune diseaseLaura Agate
Department of Endocrinology, University of Pisa, Via Paradisa 2, Pisa, Italy
J Clin Endocrinol Metab 93:2729-36. 2008..An increase in the prevalence of thyroid autoantibodies (ATAs) was reported 6-8 yr after the Chernobyl accident in radiation-exposed children and adolescents... - All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genesRossella Elisei
Department of Endocrinology and Metabolism, University of Pisa, Italy
J Clin Endocrinol Metab 90:2403-11. 2005..The finding of a basal and RA-induced RARbeta mRNA expression only in cell lines responding to all-trans-RA suggests that the growth inhibition might be mediated by RARbeta... - BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancerCristina Romei
Departments of Endocrinology and Metabolism Oncology Surgery, University of Pisa, 56100 Pisa, Italy
Endocr Relat Cancer 15:511-20. 2008.... - RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general populationRossella Elisei
Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy
J Clin Endocrinol Metab 89:3579-84. 2004..A putative role of the G691S polymorphism as genetic modifier in the normal subjects remains to be established... - BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomasEfisio Puxeddu
Dipartimento di Medicina Interna, Universita di Perugia, Perugia
J Clin Endocrinol Metab 89:2414-20. 2004.... - Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinomaFulvio Basolo
Dipartimento di Oncologia, Universita degli Studi di Pisa, Pisa Fondazione Senatore Pascale, Naples, Italy
Am J Pathol 160:247-54. 2002..In conclusion, we postulate that the correlation between the RET/PTC rearrangement type and the aggressiveness of human PTC is related to the efficiency with which the oncogene subtype delivers mitogenic signals to thyroid cells...